The realities of dyslipidaemia in metabolic syndrome and diabetes

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue SUPPL. 1, 2005, Pages

  Barter, Philip ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

Atherosclerosis; Dyslipidaemia; HDL; Insulin resistance; Metabolic syndrome; Type 2 diabetes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ARTERY WALL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BEHAVIOR MODIFICATION; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG FORMULATION; DRUG RELEASE; DYSLIPIDEMIA; ENDOTHELIUM CELL; FREQUENCY ANALYSIS; HUMAN; INFLAMMATORY CELL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID METABOLISM; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROTEIN FUNCTION; RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 24944484946     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651405005001s0301     Document Type: Article

References (38)

1. Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33:393-403.
2. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004; 318:680-3.
3. Clay MA, Pyle DH, Rye KA, Vadas MA, Gamble JR, Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 2001;157:23-9.
4. Hernandez C, Lecube A, Barbera G, Chacon P, Lima J, Simo R. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit 2003; 9:CR114-CR119.
5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
6. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41.
7. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256:2835-8.
8. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.
9. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-7.
10. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.
11. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(suppl):S11-S20.
12. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-7.
13. Wyszynski DF, Waterworth DM, Barter PJ et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005;95:194-8.
14. Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003;4:228-36.
15. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.
16. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89:2601-07.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
18. Balkau B, Charles MA, Drivsholm T et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment for high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
20. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available at www.idf.org, last accessed May 2005.
21. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999;40:1-16.
22. Hanyu O, Miida T, Obayashi K et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 2004;174: 385-90.
23. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002; 80:753-69.
24. de Vries R, Borggreve SE, Dullaart RP. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003; 49:601-13.
25. Jeppesen J, Hollenbeck CB, Zhou MY et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995; 15:320-4.
26. Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33:393-403.
27. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69.
28. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004;109:1022-8.
29. Wilhelm MG, Cooper AD. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb 2003; 10:132-9.
30. Floren CH, Albers JJ, Bierman EL. Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta 1981;663:336-49.
31. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.
32. Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 2005;54: 227-34.
33. Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.
34. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Publication No. 02-5215, 2002.
35. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
36. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22.
37. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C; European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68.
38. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5:1385-98.